Clinical Trial Update: Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 clinical trial evaluating alanosine in patients with progressive or recurrent malignant gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Alanosine (alanosine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED